{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:13:47Z","timestamp":1792192427771,"version":"4.4.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A limited number of drugs are available to treat patients with polycythemia vera (PV) and essential thrombocythemia (ET). We attempted to identify alternative agents that may target abnormalities within malignant hematopoietic stem (HSCs) and progenitor cells (HPCs). Previously, MDM2 protein levels were shown to be upregulated in PV\/ET CD34+ cells, and exposure to a nutlin, an MDM2 antagonist, induced activation of the TP53 pathway and selective depletion of PV HPCs\/HSCs. This anticlonal activity was mediated by upregulation of p53 and potentiated by the addition of interferon-\u03b12a (IFN-\u03b12a). Therefore, we performed an investigator-initiated phase 1 trial of the oral MDM2 antagonist idasanutlin (RG7388; Roche) in patients with high-risk PV\/ET for whom at least 1 prior therapy had failed. Patients not attaining at least a partial response by European LeukemiaNet criteria after 6 cycles were then allowed to receive combination therapy with low-dose pegylated IFN-\u03b12a. Thirteen patients with JAK2 V617F+ PV\/ET were enrolled, and 12 (PV, n = 11; ET, n = 1) were treated with idasanutlin at 100 and 150 mg daily, respectively, for 5 consecutive days of a 28-day cycle. Idasanutlin was well tolerated; no dose-limiting toxicity was observed, but low-grade gastrointestinal toxicity was common. Overall response rate after 6 cycles was 58% (7 of 12) with idasanutlin monotherapy and 50% (2 of 4) with combination therapy. Median duration of response was 16.8 months (range, 3.5-26.7). Hematologic, symptomatic, pathologic, and molecular responses were observed. These data indicate that idasanutlin is a promising novel agent for PV; it is currently being evaluated in a global phase 2 trial. This trial was registered at www.clinicaltrials.gov as #NCT02407080.<\/jats:p>","DOI":"10.1182\/blood.2018893545","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T21:44:00Z","timestamp":1559771040000},"page":"525-533","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":87,"title":["Oral idasanutlin in patients with polycythemia vera"],"prefix":"10.1182","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"first","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lu","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Kosiorek","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Virtgaym","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Xia","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lonette","family":"Sandy","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"Mays Cancer Center, University of Texas at San Antonio, San Antonio, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Petersen","sequence":"additional","affiliation":[{"name":"Department of Pathology and Tumor Cytogenomics, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noushin","family":"Farnoud","sequence":"additional","affiliation":[{"name":"Center for Hematologic Malignancies, Memorial Sloan Kettering, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Najfeld","sequence":"additional","affiliation":[{"name":"Department of Pathology and Tumor Cytogenomics, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit","family":"Rampal","sequence":"additional","affiliation":[{"name":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9912-1085","authenticated-orcid":false,"given":"Amylou","family":"Dueck","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1 suppl 1","key":"2020021108435170700_B1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bbmt.2006.11.003","article-title":"Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment","volume":"13","author":"Hoffman","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl","key":"2020021108435170700_B2","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.clml.2016.02.016","article-title":"A concise update on risk factors, therapy, and outcome of leukemic transformation of myeloproliferative neoplasms","volume":"16","author":"Mascarenhas","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2020021108435170700_B3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.exphem.2015.06.007","article-title":"Pathogenesis of myeloproliferative neoplasms","volume":"43","author":"Skoda","year":"2015","journal-title":"Exp Hematol"},{"issue":"6","key":"2020021108435170700_B4","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larr\u00e1n","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2020021108435170700_B5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/leu.2015.326","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone","volume":"30","author":"Kiladjian","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"2020021108435170700_B6","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.exphem.2010.03.005","article-title":"Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway","volume":"38","author":"Lu","year":"2010","journal-title":"Exp Hematol"},{"issue":"15","key":"2020021108435170700_B7","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2012-02-410712","article-title":"Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-\u03b1 2a specifically targets JAK2V617F-positive polycythemia vera cells","volume":"120","author":"Lu","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2020021108435170700_B8","first-page":"88","article-title":"MDM2 and MDMX: alone and together in regulation of p53","volume":"1","author":"Shadfan","year":"2012","journal-title":"Transl Cancer Res"},{"issue":"2","key":"2020021108435170700_B9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and p53 in oncogenesis and cancer therapy","volume":"13","author":"Wade","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2020021108435170700_B10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-12-0053","article-title":"Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy","volume":"19","author":"Li","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2020021108435170700_B11","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1158\/1078-0432.CCR-07-5136","article-title":"Targeting the MDM2-p53 interaction for cancer therapy","volume":"14","author":"Shangary","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2020021108435170700_B12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2013-11-536854","article-title":"The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon \u03b1 2a target JAK2V617F-positive progenitor and stem cells","volume":"124","author":"Lu","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2020021108435170700_B13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.116.116","article-title":"Phase 1\/1b study of RG7388, a potent MDM2 antagonist, in acute myelogenous leukemia (AML) patients (Pts) [abstract]","volume":"124","author":"Yee","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020021108435170700_B14","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2020021108435170700_B15","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.3324\/haematol.2015.139717","article-title":"Acute myeloid leukemia patients\u2019 clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts","volume":"101","author":"Reis","year":"2016","journal-title":"Haematologica"},{"issue":"14","key":"2020021108435170700_B16","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1158\/1078-0432.CCR-14-0460","article-title":"Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach","volume":"20","author":"Higgins","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2020021108435170700_B17","doi-asserted-by":"crossref","unstructured":"Siu\n              LL\n            , ItalianoA, MillerWH, et al Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors [abstract]. J Clin Oncol. 2014;32(suppl 15). Abstract 2535.","DOI":"10.1200\/jco.2014.32.15_suppl.2535"},{"issue":"23","key":"2020021108435170700_B18","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"33","key":"2020021108435170700_B19","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs [published correction appears in J Clin Oncol. 2012;30(36):4590]","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"22","key":"2020021108435170700_B20","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"14","key":"2020021108435170700_B21","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/bioinformatics\/bts280","article-title":"Exploring single-sample SNP and INDEL calling with whole-genome de novo assembly","volume":"28","author":"Li","year":"2012","journal-title":"Bioinformatics"},{"issue":"7571","key":"2020021108435170700_B22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"issue":"7571","key":"2020021108435170700_B23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nature15394","article-title":"An integrated map of structural variation in 2,504 human genomes","volume":"526","author":"Sudmant","year":"2015","journal-title":"Nature"},{"issue":"1","key":"2020021108435170700_B24","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/s41598-018-19921-x","article-title":"The MDM2-p53 pathway is involved in preconditioning-induced neuronal tolerance to ischemia","volume":"8","author":"Vecino","year":"2018","journal-title":"Sci Rep"},{"issue":"10","key":"2020021108435170700_B25","first-page":"1023","article-title":"Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation","volume":"2","author":"Yang","year":"2003","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"2020021108435170700_B26","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/onc.2011.313","article-title":"JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms","volume":"31","author":"Nakatake","year":"2012","journal-title":"Oncogene"},{"issue":"7","key":"2020021108435170700_B27","first-page":"946","article-title":"Mutations in the P53 and RAS family genes are associated with tumor progression of BCR\/ABL negative chronic myeloproliferative disorders","volume":"7","author":"Gaidano","year":"1993","journal-title":"Leukemia"},{"issue":"5","key":"2020021108435170700_B28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","article-title":"p53 lesions in leukemic transformation","volume":"364","author":"Harutyunyan","year":"2011","journal-title":"N Engl J Med"},{"issue":"14","key":"2020021108435170700_B29","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2020021108435170700_B30","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.3324\/haematol.2016.152363","article-title":"Genomic analysis of myeloproliferative neoplasms in chronic and acute phases","volume":"102","author":"Courtier","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"2020021108435170700_B31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/leu.2017.230","article-title":"Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status","volume":"32","author":"Kubesova","year":"2018","journal-title":"Leukemia"},{"issue":"8","key":"2020021108435170700_B32","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1158\/0008-5472.CAN-12-2807","article-title":"MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models","volume":"73","author":"Tovar","year":"2013","journal-title":"Cancer Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/6\/525\/1557824\/blood893545.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/6\/525\/1557824\/blood893545.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:25:50Z","timestamp":1581413150000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/6\/525\/260738\/Oral-idasanutlin-in-patients-with-polycythemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,8]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,8,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2018893545","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,8]]}}}